Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International and a global drug discovery and development services company, providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announced the appointment of Laurie Heilmann as Chief Business Officer.
Dr Jean-Pierre Wery, Crown Bioscience CEO, said: “Laurie is the ideal leader for our strategic commercial operations, possessing a diverse therapeutic background and over three decades of experience aligning sales and marketing with R&D to steer company strategy.
“As Senior VP of Global Strategy, Business Development and Marketing, Laurie led Crown Bioscience through three years of sustained, exponential growth and guided expansion of our innovative scientific technology platform. I am excited to continue working closely with Laurie to provide our clients with the insight and understanding they need to advance their preclinical research projects."
Laurie Heilmann, former Sr VP of Global Strategy, Business Development and Marketing at Crown Bioscience, said: “I am honoured to be assuming the role of Chief Business Officer at Crown Bioscience. I look forward to continuing to work with Dr Wery and our talented, dedicated team of scientists, business development and marketing professionals building our translational technology platform to help our clients address global health challenges."
Heilmann is an active member of numerous industry organisations and holds a bachelor's degree in science and business administration.
She has a therapeutic and life science technology background, including cardiovascular, oncology, immunology and metabolic disease experience and more than three decades of global experience aligning sales and marketing with R&D to steer company strategy.
As Chief Business Officer, Heilmann will be responsible for world-wide sales, strategy and marketing at Crown Bioscience.
